Reddit Posts
Newron Pharmaceuticals- the next level
Caremax ($CMAX) - the next highly volatile highly speculative play
$PIII last run to $4-$5 Announces Third-Quarter and Year-to-Date 2023 Results
$PIII The company provides preliminary full-year Adjusted EBITDA guidance for 2024, projecting a positive $20 million to $40 million
Maximize your gains with these insider-backed penny stocks.
DISH Network: Ransomware attack and major PII leak
Mentions
China expires in 2026, as does Brazil and India. Sandoz already has portions of investor presentations dedicated to the generic GLP-1 opportunity. "Most significantly, its patent in China is set to expire in 2026, which means that the entry of generics could make China the largest market for semaglutide medications. Ozempic was approved in China in 2021. Currently, at least 15 Chinese pharmaceutical companies are developing generic versions, with 11 candidates in final-stage clinical trials. Major companies such as United Laboratories, CSPC Pharmaceutical Group, and Huadong Medicine are expecting launches of their generics between 2025 and 2027." (https://journals.library.columbia.edu/index.php/stlr/blog/view/653) "Semaglutide will be under patent in many countries until the early 2030s. **However, its patent will expire in several countries starting in 2026. This includes large countries such as India, Canada, China, Brazil and Turkey which make up 40% of the world’s population and an estimated 33% of the world’s population of adults living with obesity (see Figure 1).** Interesting dynamics will be observed in each country, such as in India, where off-patent semaglutide will enter the market within a year of the launches of both Lilly’s Mounjaro (launched March 2025) and Novo’s Wegovy (launched June 2025), marking a short timeframe in which these originators can gain patient share before increased competition. Given India's significant role in the generic pharmaceutical market, this development is expected to be positively received by manufacturers, healthcare providers, and patients. The Indian government's Production-Linked Incentive (PLI) scheme, which incentivises domestic manufacturing, has spurred significant interest from leading domestic pharmaceutical companies in developing their own version. Over 10 companies have filed Subject Expert Committee (SEC) submissions in India to conduct Phase III studies for semaglutide, with 7 of them focusing on oral semaglutide, seemingly looking to differentiate away from the most common presentation. In addition, Indian companies have begun laying the groundwork for international expansion with Biocon partnering with Biomm who will file and commercialise their off-patent candidate in Brazil. China is an equally formidable manufacturing powerhouse and there 17 candidates have progressed to PIII clinical trials or are in the pre-market application stage, with 9 of them specifically running trials in obesity. Amongst these manufacturers are competent players with prior experience in commercialising GLP-1s and so intense competition is anticipated in the coming years." (https://www.iqvia.com/locations/emea/blogs/2025/07/off-patent-semaglutide)
$WING Wingstop: +26.85% $FTAI FTAI Aviation: +26.56% $PIII P3 Health Partners: +25.86% $GNRC Generac: +19.61% $TER Teradyne: +18.88% $PTON Peloton Interactive: +18.77% $MCRB Seres Therapeutics: +18.52%
Friends, what do you think of the PIII event? Will it go up today?
Everyone, I'm looking to get into 2 stocks, PIII and DGLY, what do you think?
Today HOPE for: STAI DGLY PIII Today lost: CYN GMPX
Yay, PIII went green! I'm going to take my €0.5 profit and get a coffee.
P3 Health Partners (NASDAQ: PIII) has announced preliminary guidance for 2025 and a proposed financing transaction. The company targets profitability in 2025 with projected revenues between $1.350 billion and $1.500 billion and Adjusted EBITDA ranging from negative $35 million to positive $5 million. CEO Aric Coffman noted that the company is on track with its $130+ million EBITDA growth initiatives and expects to issue full 2025 guidance with Q4 2024 earnings. P3 is in discussions for a $30 million unsecured promissory note and warrants, similar to a December 2024 transaction. This financing is subject to approval by independent directors and final documentation. The guidance includes an estimated 108,000 to 118,000 at-risk members by the end of 2025. The company emphasizes that these projections are subject to change based on various factors, and no obligation to update estimates is assumed.
Thanks for GNPX - lost 1k usd :( Now jumped to PIII. Maybe one more lost?
A think you’re missing that most of the earnings are priced in. Analysts are just looking at quarterly growth but macro indicators and pipeline. Like a biotech can miss earnings but if they’ve made material advances in other PI-PIII trials, that can be much more valuable over the long run
Newron Pharmaceuticals- Potential 10 bagger I was participating at a Investor Conferene late November and regarding the next crucial and impactful news. Here's what I heard of the CEO: "We have massive new flow to come in the next six months, starting the next few weeks with the announcement of completion of enrollment of our first pivotal study in non-TRS schizophrenia. That should happen anytime next few weeks. That means for everybody knowing that two or three months later our study with up to 290 patients in non TRS schizophrenia will report results first quarter next year. Before that, what we can tell you is that we will have the final results from a phase two study, of our compound in TRS in treatment resistance, schizophrenia early January. This should be expected. Then we will talk about the partnering and then we talk about the start of the second pivotal study in TRS later in the second quarter. And that means the next six months you will have at least five news points from Newron, each of one that can substantially change the value of our stock on the stock market" Just to let you know, Karuna was taken over last week for 14 Billion $, because of their PIII schizophrenia drug. Newrons Evenamide is on the transition to PIII and their market cap is less than 100 Mio $! Even tough the days between christmas and new years eve are usually silent, the shareprice jumped yesterday for more than 10% with unusual high volume. The next news are around the corner and Newron Pharmaceuticals could be a 10 bagger!
 $PIII ON MY WATCH!!!!
Very nice to see the increased guidance from $PIII
good place to add! $PIII #NASDAQ!
What do y’all think about P3 Health Partners (PIII)
What y’all think about PIII (P3 Health Partners)
PIII is an easy move. CFO and 10% owner went in big this week
Nah I’m in PIII and SMCI
PIII in a hard up trend and no one knows about it
Also, I dunno how high PIII will go but it’s been a beautiful monthly chart and hourly plays *chefs kiss
I’m liking PIII today for hourly plays
PIII and PIIIW goin to fly for next couple of weeks
*Today's Price Target Initiations:* **$ENVX** Cowen & Co. analyst Gabe Daoud initiates coverage on Enovix with a Outperform rating and announces Price Target of $32 **$CDRO** Stifel initiates coverage on Codere Online Luxembourg with a Buy rating and announces Price Target of $10 **$VIEW** Raymond James analyst Pavel Molchanov maintains View with a Outperform and lowers the price target from $9 to $7 **$BOXD** BTIG analyst Marvin Fong initiates coverage on Boxed with a Neutral rating **$PIII** William Blair analyst Ryan Daniels initiates coverage on P3 Health Partners with a Outperform rating **$AMPS** Altus Power initiated with a buy and $13 PT at Citigroup
Did I miss the news on P3 Health (PIII/PIIIW) or just general deSPAC cliff diving?